RCM Technologies, Inc. — Form 10-Q Summary
Period clarification: The filing is for the thirteen weeks ended April 1, 2023, compared with the thirteen weeks ended April 2, 2022. Although the request metadata says “2022 Q1,” the filing itself reports first-quarter 2023 results. Financial figures below are in U.S. dollars and generally rounded to millions.
Business context and reporting period
RCM provides engineering, specialty healthcare staffing, life sciences, and information technology services. Its reportable segments are Specialty Health Care, Engineering, and Life Sciences and IT. The unaudited interim statements cover 13 weeks; the company cautions that quarterly results are not necessarily indicative of full-year results.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Revenue | $67.1 million | $82.0 million | Down 18.1% |
| Gross profit / margin | $19.0 million / 28.3% | $23.4 million / 28.6% | Profit down $4.4 million |
| Operating income / margin | $5.7 million / 8.5% | $9.0 million / 11.0% | Down $3.3 million |
| Net income | $3.8 million | $6.5 million | Down 41.1% |
| Diluted earnings per share | $0.41 | $0.62 | Down $0.21 |
| Cash from operations | $(0.8) million | $2.5 million | Declined $3.3 million |
- Revenue fell primarily because Specialty Health Care revenue declined $13.0 million as COVID-19-related demand receded. Engineering revenue declined $1.4 million; Life Sciences and IT declined $0.4 million.
- Specialty Health Care revenue was $39.1 million, down 25.0%; segment operating income was $4.3 million versus $6.9 million. Engineering revenue was $18.5 million, down 7.1%, and operating income was $0.4 million versus $1.0 million. Life Sciences and IT revenue was $9.5 million, down about 4%; operating income was $1.0 million versus $1.1 million.
- At April 1, 2023, cash was $1.8 million, accounts receivable net was $58.8 million, current assets were $68.8 million, and current liabilities were $43.4 million, implying working capital of approximately $25.4 million.
- Line-of-credit borrowings were $19.2 million, up from $8.8 million at year-end; the company reported $23.8 million of additional availability under its $45.0 million facility. Its effective average borrowing rate, including unused fees, was 6.0%, versus 1.6% a year earlier. The company said it was covenant-compliant.
- Operating cash use reflected, among other items, an $8.0 million increase in accounts receivable. Investing cash use was $0.3 million, principally for property and equipment. The cash flow statement reports $2.4 million of net financing cash provided, including $8.2 million of stock repurchases.
Material changes, outlook, and risks
- Gross margin was slightly lower overall, while SG&A decreased in dollars but increased to 19.9% of revenue from 17.2%, contributing to weaker operating margins. Interest expense and other expense rose to $0.4 million from $0.1 million, mainly due to higher borrowing.
- A $0.4 million gain recorded in the quarter related to final escrow proceeds from the 2021 sale of Canadian Power Systems assets. It partially offset lower Engineering results.
- Management said Specialty Health Care demand remains above pre-pandemic levels and believes the segment is positioned for revenue growth, subject to seasonality; it also noted that the overall effect of declining COVID-related demand and other demand trends is uncertain. The filing provides no consolidated numerical revenue or earnings guidance.
- Management said it believes liquidity is sufficient for at least the next 12 months. The revolving facility was amended and restated on April 24, 2023, retaining a $45.0 million commitment and extending maturity to April 24, 2026.
- After quarter-end, the board authorized an additional $25.0 million share-repurchase program. Through May 9, the company reported purchasing 595,910 shares for $7.1 million at an average $11.92 per share; $23.9 million remained available under the new program.
- Customer concentration remains significant: two Specialty Health Care customers represented 19.4% and 10.5% of quarterly consolidated revenue. Other stated risks include economic cyclicality, customer collection risk, competition and pricing pressure, employee recruitment and retention, wage and regulatory changes, foreign exchange, insurance claims, and cyber risk.
- The company reported $2.6 million accrued for asserted claims. For an Industrial Processing client dispute, it reserved $0.5 million; the company believes contractual damages may be capped at $3.3 million and insurance may apply, but it gives no assurance of either limit or coverage.
- Disclosure controls were deemed ineffective because material weaknesses in IT general controls over the SAP financial system continued at April 1, 2023. Management said the weaknesses had not caused a financial-statement misstatement and remediation is underway; timing of full remediation remains uncertain. The company also expects a financial-system upgrade or replacement to cost $0.5–$1.0 million, with go-live expected in 2024.
Important facts for investors to verify
- Confirm the applicable reporting period: this filing covers Q1 2023, not Q1 2022.
- Review the decline and subsequent trajectory of Specialty Health Care demand, including the effects of COVID-related normalization and customer concentration.
- Track receivable growth, collections, operating cash conversion, credit-facility utilization, and borrowing costs.
- Assess the status and potential exposure of legal claims, particularly the Industrial Processing dispute and insurance coverage.
- Monitor remediation and independent validation of the disclosed material weaknesses in internal control over financial reporting.
- Reconcile apparent figures in the filing: MD&A reports current liabilities of $42.9 million and working capital of $25.9 million, while the balance sheet lists current liabilities of $43.4 million, implying working capital of about $25.4 million. MD&A also reports $2.9 million of financing cash provided, versus $2.4 million in the cash flow statement; share-repurchase cash use is likewise described differently in MD&A and the statements.